Journal
JOURNAL OF CARDIAC FAILURE
Volume 22, Issue 5, Pages 340-346Publisher
CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
DOI: 10.1016/j.cardfail.2015.12.004
Keywords
Heart failure; epigenetic; inflammation
Categories
Funding
- PHS Grant from the Clinical and Translational Science Award Program, National Institutes of Health, National Center for Advancing Translational Sciences [UL1TR000454]
- National Institutes of Health National Institute of Nursing Research grant [T32NR012715, 1F31NR015180-01]
Ask authors/readers for more resources
Background: Heart failure (HF) is associated with inflammation characterized by the formation of the inflammasome, which triggers maturation of inflammatory cytokines. Apoptosis-associated speck-like protein with a caspase recruitment domain (ASC), a vital component of the inflammasome, is controlled through epigenetic modification, which may be a candidate pathway for worsening HF. This study examined the inflammasome pathway in HF and the relationships between ASC CpG methylation and outcomes in HF. Methods and Results: Stored samples from 155 HF outpatients (ejection fraction 29.9 +/- 14.9%) were analyzed for percentage methylation of 7 CpG sites in the intron region preceding exon 1 of the ASC gene. ASC methylation was inversely related to ASC mRNA (r = -0.33; P <.001) and protein (r = -0.464; P <.001). ASC methylation had a positive linear relationship with ejection fraction (r = 0.85; P <.001), quality of life (r = 0.83; P <.001), and 6-minute walk test (r = 0.59; P =.023) and a negative linear relationship with depression (r = -0.81; P <.001) and anxiety (r = -0.75; P <.001). Higher ASC methylation was associated with a lower risk for clinical events (hazard ratio [HR] 0.16; P =.025), whereas higher protein (HR = 1.78; P =.045) and mRNA expression (HR = 1.18; P =.05) were associated with a greater risk. Conclusions: Increased methylation of CpG sites in the intron region of ASC is associated with improved outcomes in HF. The associated decrease in ASC expression implicates this inflammatory mediator as a possible driver of HF outcomes and may represent a therapeutic target.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available